secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001140361-23-039357
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences provides H1 2023 financials of target Beijing Continent; revenue up 21% YoY
--------------------------------------------------------------------------------

- BC revenue RMB379.3M, net profit RMB81.2M for H1 2023 vs revenue RMB312.7M, net profit RMB63.9M in H1 2022.
- BC main product ETUARY for idiopathic pulmonary fibrosis; gross margin 96% in H1 2023.
- BC total assets RMB806.6M, equity RMB707.8M as of June 30, 2023.
- Catalyst's acquisition of indirect controlling interest in BC subject to stockholder approval; proxy mailed July 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/0001140361-23-039357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/brhc20056996_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer